Literature DB >> 31472737

Use of Claims Data for Cost and Cost-Effectiveness Research.

Ya-Chen Tina Shih1, Lei Liu2.   

Abstract

Administrative claims data are big data generated from healthcare encounters. Claims data contain information on insurance payment as well as clinical diagnoses and procedure codes to ascertain medical conditions and treatments, making them valuable sources for economic evaluation research. This paper offers an introductory overview of the use of claims data for oncology-related cost-of-illness, cost comparison, and cost-effectiveness analyses. We reviewed analytical methods commonly employed in these analyses, such as the phase of care approach and net costing method for cost-of-illness studies, propensity score matching methods for cost comparison studies, and net benefit regression models for cost-effectiveness studies. We used published studies to explain each method and to discuss methodological challenges of conducting economic studies using claims data.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31472737      PMCID: PMC6719724          DOI: 10.1016/j.semradonc.2019.05.009

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  25 in total

1.  An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a medicare population.

Authors:  Jack Hadley; Daniel Polsky; Jeanne S Mandelblatt; Jean M Mitchell; Jane C Weeks; Qin Wang; Yi-Ting Hwang
Journal:  Health Econ       Date:  2003-03       Impact factor: 3.046

2.  Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis.

Authors:  Jeffrey S Hoch; Andrew H Briggs; Andrew R Willan
Journal:  Health Econ       Date:  2002-07       Impact factor: 3.046

3.  Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020.

Authors:  Angela B Mariotto; K Robin Yabroff; Eric J Feuer; Roberta De Angelis; Martin Brown
Journal:  Cancer Causes Control       Date:  2006-12       Impact factor: 2.506

4.  Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States.

Authors:  B Ashleigh Guadagnolo; Kai-Ping Liao; Linda Elting; Sharon Giordano; Thomas A Buchholz; Ya-Chen Tina Shih
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

5.  Semiparametric Estimation of Longitudinal Medical Cost Trajectory.

Authors:  Liang Li; Chih-Hsien Wu; Jing Ning; Xuelin Huang; Ya-Chen Tina Shih; Yu Shen
Journal:  J Am Stat Assoc       Date:  2018-06-18       Impact factor: 5.033

6.  Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.

Authors:  Hubert Y Pan; Jing Jiang; Karen E Hoffman; Chad Tang; Seungtaek L Choi; Quynh-Nhu Nguyen; Steven J Frank; Mitchell S Anscher; Ya-Chen Tina Shih; Benjamin D Smith
Journal:  J Clin Oncol       Date:  2018-03-21       Impact factor: 44.544

7.  Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis.

Authors:  Daisuke Goto; Ya-Chen Tina Shih; Pascal Lecomte; Melvin Olson; Chukwukadibia Udeze; Yujin Park; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

8.  Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.

Authors:  Fadia T Shaya; Ian M Breunig; Brian Seal; C Daniel Mullins; Viktor V Chirikov; Nader Hanna
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

9.  Cost of care for elderly cancer patients in the United States.

Authors:  K Robin Yabroff; Elizabeth B Lamont; Angela Mariotto; Joan L Warren; Marie Topor; Angela Meekins; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

10.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

Authors:  Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats
Journal:  JAMA       Date:  2016-09-13       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.